Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer

BJU International

Volumn 99, Issue 4, 2007, Pages 817-820

  Gårdmark, Truls ^a   Jahnson, Staffan ^a   Wahlquist, Rolf ^a   Wijkström, Hans ^a   Malmström, Per Uno ^a  

^a Surgical Sciences ^*  (Norway)

Author keywords

BCG; Bladder cancer; Intravesical; Long term; Mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 33947331558     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06706.x     Document Type: Article

References (12)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6
2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3
3. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C; European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-12
4. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697-701
5. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66 (Suppl. 1): 108-25
6. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004; 27: 522-8
7. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93: 485-90
8. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
9. Lundholm C, Norlen BJ, Ekman P et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996; 156: 372-6
10. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161: 1124-7
11. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9
12. Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001; 93: 597-604